Back to Agenda
[V6-S5] Various Issues Related to HTA -Looking at on a Micro and Macro Scale-
Session Chair(s)
Koji Kawakami, MD, PhD
Professor and Chair, Department of Pharmacoepidemiology
Graduate School of Medicine and Public Health, Kyoto University, Japan
For pharmaceutical and medical device industry, it becomes more and more important to explain the value of new technology, facing the introduction of HTA in Japan. Following presentations will be made in this session; - Examples of the utilization of Real World Data, as well as the latest trend of HTA in Japan. - The function of HEOR in US and EU, which covers various approaches such as cost-effectiveness analysis, budget impact and disease burden. - Tips of the Guideline of Central Social Insurance Medical Council Finally, an opportunity for an exchange of views between panelists and audience will be provided through panel-discussion.
Speaker(s)
Real World Data Development for the Drug Evaluation
Koji Kawakami, MD, PhD
Graduate School of Medicine and Public Health, Kyoto University, Japan
Professor and Chair, Department of Pharmacoepidemiology
HEOR Function in US and EU
Mark Hill, MD, PhD
Shionogi Limited, United Kingdom
Head, Global Market Access
Remarks on Chuikyo Guideline
Kosuke Iwasaki, MBA
Milliman, Inc., Japan
Japan Healthcare Practice and Data Analytics
Have an account?